van Weijsten M J, Venrooij K R, Lelieveldt L P W M, Kissel T, van Buijtenen E, van Dalen F J, Verdoes M, Toes R E M, Bonger K M
Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Institute for Chemical Immunology, 6525 GA Nijmegen, The Netherlands.
Mol Pharm. 2024 Feb 5;21(2):481-490. doi: 10.1021/acs.molpharmaceut.3c00527. Epub 2023 Oct 20.
Many autoimmune diseases are characterized by B cells that mistakenly recognize autoantigens and produce antibodies toward self-proteins. Current therapies aim to suppress the immune system, which is associated with adverse effects. An attractive and more specific approach is to target the autoreactive B cells selectively through their unique B-cell receptor (BCR) using an autoantigen coupled to an effector molecule able to modulate the B-cell activity. The cellular response upon antigen binding, such as receptor internalization, impacts the choice of effector molecule. In this study, we systematically investigated how a panel of well-defined mono-, di-, tetra-, and octavalent peptide antigens affects the binding, activation, and internalization of the BCR. To test our constructs, we used a B-cell line expressing a BCR against citrullinated antigens, the main autoimmune epitope in rheumatoid arthritis. We found that the dimeric antigen construct has superior targeting properties compared to those of its monomeric and multimeric counterparts, indicating that it can serve as a basis for future antigen-specific targeting studies for the treatment of RA.
许多自身免疫性疾病的特征是B细胞错误地识别自身抗原并产生针对自身蛋白的抗体。目前的治疗方法旨在抑制免疫系统,这会带来不良反应。一种有吸引力且更具特异性的方法是通过抗原与能够调节B细胞活性的效应分子偶联,利用自身反应性B细胞独特的B细胞受体(BCR)来选择性地靶向这些B细胞。抗原结合后的细胞反应,如受体内化,会影响效应分子的选择。在本研究中,我们系统地研究了一组明确的单价、二价、四价和八价肽抗原如何影响BCR的结合、激活和内化。为了测试我们构建的抗原,我们使用了一种表达针对瓜氨酸化抗原(类风湿性关节炎中的主要自身免疫表位)的BCR的B细胞系。我们发现,与单体和多聚体对应物相比,二聚体抗原构建体具有更优异的靶向特性,这表明它可为未来治疗类风湿性关节炎的抗原特异性靶向研究奠定基础。